InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-10.5%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by LAMATTINA JOHN L, Director. Officer active across 2 companies, notably Immunome Inc.. Cumulatively, 11 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €10k. History available since 24 May 2021. The latest transaction was filed on 27 November 2024 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations11 total
2,406 shares@ US$52.3030.4% of flowCommon StockSEC:0002001011-24-000093:0
1,252 shares0Common StockSEC:0002001011-24-000059:0
1,142 shares0Common StockSEC:0000886163-23-000042:0
15,125 shares@ US$4.0084.5% of flowCommon StockSEC:0001104659-23-004007:0
1,004 shares0Common StockSEC:0000886163-22-000079:0
4,835 shares@ US$32.300.0037% mcap50.0% of flowCommon StockSEC:0000886163-21-000136:0
4,835 shares@ US$32.3034.8% of flowCommon StockSEC:0000886163-21-000136
630 shares0Common StockSEC:0000886163-21-000089:0
630 shares0Common StockSEC:0000886163-21-000089
338 shares@ US$18.440.0002% mcap50.0% of flowCommon StockSEC:0001104659-21-072617:0
Ideal exit: 18 Feb 2022 (T+270)
338 shares@ US$18.4450.0% of flowCommon StockSEC:0001104659-21-072617
Ideal exit: 18 Feb 2022 (T+270)
11 of 11 declarations
About LAMATTINA JOHN L
John L. Lamattina is a Board Member at Immunome Inc. and Ligand Pharmaceuticals Inc. In this role, he contributes to overseeing the activities of the companies and making strategic decisions. Lamattina brings his expertise in corporate governance and biopharmaceuticals, which is essential for guiding the direction of the organizations. His commitment to innovation and research is an asset to the boards.
